Cycrosporin A (Cy A), a potent immunosuppressive drug, markedly inhibited IL-2 production of Jurkat cells whereas it did not affect the IL-2R expression. Thus, the mechanism of action of Cy A appears to differ from that of the protein kinase inhibitor, H-7, and the calmodulin inhibitor...
IL-2 was first identified as a growth factor capable of driving the expansion of activated human T cell populations. In the more than 40 years since its discovery, a tremendous amount has been learned regarding the mechanisms that regulate the expression of both IL-2 and its cell surface rece...
Kaplan–Meier estimator and proportional hazard Cox regression models were used for drug survival analysis. Results A total of 4866 treatment courses (4178 patients)—overall time of exposure of 9500 patient-years—were included in this study, with 3164 corresponding to an IL-17 inhibitor (...
efforts to exploit IL-2 in immunotherapy were focused on promoting anti-tumour immunity [57]. High-dose recombinant IL-2 (aldesleukin; trade name Proleukin) was the first immunotherapy approved by the U.S. Food and Drug Administration (FDA) in 1992 [58,...
Immune checkpoint inhibitor IL: Interleukin OR: Overall response ORR: Objective response rate PD-1: Programmed cell death 1 PD-L1: PD ligand-1 PFS: Progression-free survival PR: Partial response RECIST: Response Evaluation Criteria in Solid Tumors SAE: Serious adverse event SD: St...
starting treatment earlier would be more helpful to prevent pancreatic damage. Also, studies with RA patients who do not have diabetes could show whether IL-1 inhibitor therapy can prevent prediabetes and T2DM in specific patient risk groups, such as those who have RA and obesity or metabolic ...
Interleukin-2 (IL-2) and its receptor (IL-2R) are essential in orchestrating immune responses. Their function and expression in the tumor microenvironment make them attractive targets for immunotherapy, leading to the development of IL-2/IL-2R-targeted t
The constituents of atovaquone and proguanil hydrochloride tablets, atovaquone and proguanil hydrochloride, interfere with 2 different pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication. Atovaquone is a selective inhibitor of parasite mitochondrial electron transport. ...
Ilginatinib (NS-018) is a highly active JAK2 inhibitor, with an IC50of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). Ilginatinib (NS-018) also inhibits Src-family kinases, especially SRC and FYN...
NMPA按照优先审评审批程序加快批准了Tremfya上市。 原文出处:TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis